Grail GRAL

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$1.68 (+4.33%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Grail (GRAL) Business Model and Operations Summary
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

Key Insights

Grail (GRAL) Core Market Data and Business Metrics
  • Latest Closing Price

    $40.18
  • Market Cap

    $1.44 Billion
  • Average Trade Volume

    1,474,979 Shares
  • Total Outstanding Shares

    35.97 Million Shares
  • CEO

    Mr. Robert P. Ragusa
  • Total Employees

    1,000
  • IPO Date

    June 12, 2024
  • SIC Description

    Services-medical Laboratories
  • Primary Exchange

    NASDAQ
  • Headquarters

    1525 O'brien Drive, Menlo Park, CA, 94025

Earnings Reports

Expected vs. Actual Quarterly Earnings-Per-Share & Revenue

Short Volume

Daily short volume activity identifies short-term trading pressure and potential price volatility

Short Interest

Short Interest

This information represents bi-monthly aggregated short interest data reported to the Financial Industry Regulatory Authority (FINRA) by broker-dealers.

Settlement Date: The date on which the short interest data is considered settled, typically based on exchange reporting schedules.

Short Interest: The total number of shares that have been sold short but have not yet been covered or closed out.

Avg Daily Volume: The average daily trading volume for the stock over the specified period, typically used to contextualize short interest.

Days To Cover: The estimated number of days it would take to cover all short positions based on average trading volume.

Bi-monthly short interest levels can be used to gauge bearish market sentiment and short squeeze potential

Revenue Breakdown

Distribution of revenue across unique business segments & geographies

Historical Stock Splits

Execution DateSplit Amount

Historical Dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about GRAL from trusted financial sources